ASX Linkedin Twitter               

 

Investors Home

Welcome to the Viralytics Investor Centre

Viralytics is an Australian biotechnology company focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells.

If you wish to receive emails about Viralytics please complete the subscription form.

 

Latest Investor Presentation

Viralytics Investor Presentation

Click image to view Presentation

 

QTC

Share Register

Link Market Services Ltd
Level 12
680 George Street
SYDNEY NSW 2000
International: +61 2 8280 7454
T: 1300 554 474

Investment highlights

  • Lead investigational product CAVATAK® with demonstrated potential across a range of indications and treatment settings
  • Opportunity for use as monotherapy or in combination with new ‘blockbuster’ agents
  • Resources to conduct key global clinical trials
  • Collaborative clinical trial program with Merck in lung and bladder cancer
  • Corporate strategy to license, partner, or sell at key value point

Following trials underway or recently completed:

CALM and CALM extension: Success in Phase 2 melanoma trial (US)

STORM / KEYNOTE-200: CAVATAK / KEYTRUDA® Collaboration with Merck in lung and bladder cancer (US & UK)

CANON: Superficial bladder cancer (UK)

MITCI: CAVATAK / YERVOY™ Melanoma (US)

CAPRA: CAVATAK / KEYTRUDA® Melanoma (US)

ASX Share Price

CodeVLA
PriceA$0.310
Information source: ASX
Data is delayed by 20 minutes




Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).